UK markets open in 1 hour 9 minutes
  • NIKKEI 225

    28,743.25
    -121.07 (-0.42%)
     
  • HANG SENG

    28,689.44
    -408.85 (-1.41%)
     
  • CRUDE OIL

    67.24
    +1.15 (+1.74%)
     
  • GOLD FUTURES

    1,702.40
    +3.90 (+0.23%)
     
  • DOW

    31,496.30
    +572.20 (+1.85%)
     
  • BTC-GBP

    36,435.39
    +576.73 (+1.61%)
     
  • CMC Crypto 200

    1,019.89
    +76.71 (+8.13%)
     
  • ^IXIC

    12,920.15
    +196.65 (+1.55%)
     
  • ^FTAS

    3,771.73
    -20.36 (-0.54%)
     

Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

·1-min read

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous
Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

04-Feb-2021 / 19:28 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 04.02.2021 - Würzburg based PENTIXAPHARM GmbH, an associate of Eckert & Ziegler AG (ISIN DE0005659700), has received confirmation from the European Medicines Agency (EMA) that its lead candidate PENTIXAFOR may be tested directly in a phase III clinical study. The agency said that there are "sufficient safety data available to initiate a phase III trial" for the Gallium-68 labelled radiodiagnostic which detects CXCR4-positiv solid tumors and CXCR4-positive hematological malignancies.

Contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel. +49 30 941084-138, karolin.riehle@ezag.de, www.ezag.de

Information and Explanation of the Issuer to this News:

Details about PENTIXAFOR and the content of the EMA advice will be provided in the next days in a separate PENTIXAPHARM press release.

04-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Eckert & Ziegler Strahlen- und Medizintechnik AG

Robert-Rössle-Str.10

13125 Berlin

Germany

Phone:

+49 30 941084-138

Fax:

+49 30 941084-112

E-mail:

karolin.riehle@ezag.de

Internet:

www.ezag.de

ISIN:

DE0005659700

WKN:

565970

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1166049


 

End of Announcement

DGAP News Service

show this
show this